Montelukast use over the past 20 years: monitoring of its effects and safety issues
Montelukast, a leukotriene receptor antagonist, was launched 20 years ago in Korea. It is recommended as an alternative treatment for asthma in children with mild persistent symptoms or as an add-on treatment to existing low-dose inhaled corticosteroids (ICSs) in children who require additional trea...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Pediatric Society
2020-10-01
|
| Series: | Clinical and Experimental Pediatrics |
| Subjects: | |
| Online Access: | http://www.e-cep.org/upload/pdf/cep-2019-00325.pdf |
| _version_ | 1818062090575806464 |
|---|---|
| author | Yong Ju Lee Chang-Keun Kim |
| author_facet | Yong Ju Lee Chang-Keun Kim |
| author_sort | Yong Ju Lee |
| collection | DOAJ |
| description | Montelukast, a leukotriene receptor antagonist, was launched 20 years ago in Korea. It is recommended as an alternative treatment for asthma in children with mild persistent symptoms or as an add-on treatment to existing low-dose inhaled corticosteroids (ICSs) in children who require additional treatment. However, in the real-world setting, many doctors and patients prefer montelukast over ICSs despite their lower efficacy. Although montelukast is considered to be a safe drug, there are concerns regarding adverse drug reactions, including the rare occurrence of Churg-Strauss syndrome and, despite insufficient data, the possibility of neuropsychiatric events such as anxiety, depression, sleep disturbance, and suicidality. This review identified that montelukast has significantly contributed to asthma control over the past 20 years in Korea and has been critical for reducing asthma severity, especially early wheezing and disease control. Our findings suggest that the effects of montelukast treatment can be monitored by measuring serum eosinophilderived neurotoxin levels. |
| first_indexed | 2024-12-10T13:58:41Z |
| format | Article |
| id | doaj.art-d3ce3d092052439893c8cab93c2403b3 |
| institution | Directory Open Access Journal |
| issn | 2713-4148 |
| language | English |
| last_indexed | 2024-12-10T13:58:41Z |
| publishDate | 2020-10-01 |
| publisher | The Korean Pediatric Society |
| record_format | Article |
| series | Clinical and Experimental Pediatrics |
| spelling | doaj.art-d3ce3d092052439893c8cab93c2403b32022-12-22T01:45:52ZengThe Korean Pediatric SocietyClinical and Experimental Pediatrics2713-41482020-10-01631037638110.3345/cep.2019.0032520125553611Montelukast use over the past 20 years: monitoring of its effects and safety issuesYong Ju Lee0Chang-Keun Kim1 Department of Pediatrics, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea Asthma and Allergy Center, Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, KoreaMontelukast, a leukotriene receptor antagonist, was launched 20 years ago in Korea. It is recommended as an alternative treatment for asthma in children with mild persistent symptoms or as an add-on treatment to existing low-dose inhaled corticosteroids (ICSs) in children who require additional treatment. However, in the real-world setting, many doctors and patients prefer montelukast over ICSs despite their lower efficacy. Although montelukast is considered to be a safe drug, there are concerns regarding adverse drug reactions, including the rare occurrence of Churg-Strauss syndrome and, despite insufficient data, the possibility of neuropsychiatric events such as anxiety, depression, sleep disturbance, and suicidality. This review identified that montelukast has significantly contributed to asthma control over the past 20 years in Korea and has been critical for reducing asthma severity, especially early wheezing and disease control. Our findings suggest that the effects of montelukast treatment can be monitored by measuring serum eosinophilderived neurotoxin levels.http://www.e-cep.org/upload/pdf/cep-2019-00325.pdfrespiratory soundsasthmamontelukastchildeosinophil-derived neurotoxin |
| spellingShingle | Yong Ju Lee Chang-Keun Kim Montelukast use over the past 20 years: monitoring of its effects and safety issues Clinical and Experimental Pediatrics respiratory sounds asthma montelukast child eosinophil-derived neurotoxin |
| title | Montelukast use over the past 20 years: monitoring of its effects and safety issues |
| title_full | Montelukast use over the past 20 years: monitoring of its effects and safety issues |
| title_fullStr | Montelukast use over the past 20 years: monitoring of its effects and safety issues |
| title_full_unstemmed | Montelukast use over the past 20 years: monitoring of its effects and safety issues |
| title_short | Montelukast use over the past 20 years: monitoring of its effects and safety issues |
| title_sort | montelukast use over the past 20 years monitoring of its effects and safety issues |
| topic | respiratory sounds asthma montelukast child eosinophil-derived neurotoxin |
| url | http://www.e-cep.org/upload/pdf/cep-2019-00325.pdf |
| work_keys_str_mv | AT yongjulee montelukastuseoverthepast20yearsmonitoringofitseffectsandsafetyissues AT changkeunkim montelukastuseoverthepast20yearsmonitoringofitseffectsandsafetyissues |